How Long Can You Take HRT?

Hot flashes and night sweats can persist for years. A woman whose symptoms remain disruptive may continue hormone therapy after discussing the benefits and risks. An arbitrary treatment anniversary does not establish that symptoms have ended or that stopping is the best choice.

The Menopause Society recommends that longer treatment have a documented indication, such as persistent vasomotor symptoms, with shared decision-making and periodic reassessment. The review should explain what the medicine is still helping and whether the current regimen remains suitable.

The commonly discussed timing guidance of younger than 60 or within 10 years of menopause concerns the balance when starting treatment. Continuing a prescription begun earlier is a different clinical question, although age and new health conditions still affect the review.

NICE describes an increased breast cancer risk with combined systemic HRT that grows with duration. The increase declines after stopping but can persist for at least 10 years. Estrogen-only treatment has a different breast cancer profile and is generally used after total hysterectomy.

Age also changes the underlying likelihood of cardiovascular and clotting events. Oral estrogen has a higher VTE risk than transdermal estrogen. Dose, route, progestogen, and new medical conditions therefore belong in a continuation review.

Changing to a patch or reducing the dose may be considered for a suitable person, but does not remove every risk. If you have a uterus, systemic estrogen still needs adequate progestogen protection. A prescription change should include the full regimen.

• Which symptoms remain and whether treatment still improves them.
• The exact hormones, doses, routes, schedule, and any difficulty using them consistently.
• Bleeding, breast changes, side effects, new diagnoses, and changes in other medicines.
• Relevant cancer, clotting, cardiovascular, liver, and family history.
• Whether a lower dose, different route, local treatment, or a trial of stopping fits your current needs.

NICE recommends a review three months after treatment starts and annually thereafter, with earlier assessment for side effects or poor response. Recommended health screening should continue. A new diagnosis or concerning symptom can require a review between routine appointments.

NICE advises offering a choice between gradually reducing HRT and stopping immediately. A gradual reduction may limit symptom recurrence in the short term, but neither approach has shown a difference in symptoms over the longer term. A universal taper schedule is not established for every prescription.

Agree on the plan before changing a combined regimen, so estrogen and progestogen are managed appropriately. Ask what symptoms to record and when to arrange review. If hot flashes return, discuss how disruptive they are and whether restarting, changing treatment, or using a nonhormonal option is appropriate.

Keep vaginal symptoms in the plan

Stopping systemic HRT does not require that every menopause treatment stop at the same time. Vaginal dryness or pain can be assessed for local treatment, which has much lower systemic exposure. Its continuation should be based on symptoms and suitability.

Systemic hormone therapy prevents bone loss and reduces fracture risk while used. That protection decreases after stopping. If you have osteoporosis, a previous fragility fracture, or significant fracture risk, discuss the ongoing bone-health plan before discontinuing it.

Premature ovarian insufficiency before 40 is a distinct situation. NICE recommends hormone replacement, unless contraindicated, until at least the usual age of natural menopause. At that stage, the decision should be reassessed using the symptoms and health risks then present.

If hormones are contraindicated, care should still address bone health, cardiovascular health, and symptoms. A specialist may be helpful when the clinical history is complex or symptoms remain difficult to manage.

Local vaginal treatment is used for symptoms such as dryness, burning, and pain with sex. NICE describes minimal systemic absorption and very rare serious adverse effects. Symptoms often return when treatment stops, so continuing treatment may be appropriate with review.

Previous breast cancer requires a specific discussion of nonhormonal options, recurrence uncertainty, and ongoing cancer medicines. Women taking an aromatase inhibitor should involve their breast cancer specialist. Local treatment should be chosen from that assessment.

At follow-up, tell the clinician which symptoms recur when treatment is reduced and which treatment you are using. That information is more useful for a continuation decision than a single rule based on age or years of use.